Role of matrix metalloproteinases in coronary artery disease

Indian Heart Journal

Volumn 61, Issue 1, 2009, Pages 44-50

  Shah, Vinod K ^b   Shalia, Kavita K ^a   Mashru, Manoj R ^b   Soneji, Surendra L ^b   Abraham, Ajin ^b   Kudalkar, Ketki V ^b   Vasvani, Jagdish B ^b   Sanghavi, Snehal T ^b  

^a Sir Hurkisondas Nurrotumdas Hospital & Research Centre   (India)

^b NONE

Author keywords

Acute myocardial infarction; Matrix metalloproteinases; Stable angina; Unstable angina

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; HEPARIN; MATRILYSIN; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ADULT; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED;

EID: 66949138615     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Visse R and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92:827-839. (Pubitemid 36542523)
2. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253:269-285. (Pubitemid 37321735)
3. Garcia-Touchard A, Henry TD, Sangiorgi G, et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol. 2005; 25:1119-1127 (Pubitemid 40776597)
4. Galis ZS and Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90:251-262. (Pubitemid 34633925)
5. Lindy O, Konttinen YT, Sorsa T, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 1997; 40: 13911399. (Pubitemid 27430949)
6. Sorsa T, Tjaderhane L and Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004; 10: 311318. (Pubitemid 39564343)
7. Jones BC, Sane DC and Herrington DM. Matrix metalloporteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812823. (Pubitemid 38366237)
8. Ravn HB and Falk E. Histopathology of plaque rupture. Cardiol Clin 1999; 17:263270. (Pubitemid 29277862)
9. Ardans JA, Blum A, Mangan PR, et al. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler Thromb Vasc Biol 2001; 21:12651268. (Pubitemid 34219830)
10. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92:1565-1569.
11. Rekhter MD, Hicks GW, Brammer DW, et al. Hypercholesterolemia causes mechanical weakening of rabbit atheroma : local collagen loss as a prerequisite of plaque rupture. Circ Res 2000; 86:101-108 (Pubitemid 30044174)
12. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin Invest 1994; 94: 2493-2503. (Pubitemid 24379627)
13. Nikkari ST, Hoyhtya M, Isola J and Nikkari T. Macrophages contain 92 kDA gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J. Pathol 1996; 149: 1427-1433. (Pubitemid 26363948)
14. Sorbi D, French DL, Nuvo GJ, et al. Elevated levels of 92 kDa type IV collagenase (matrix metalloporitenase- 9) in giant cell arteritis. Arthritis Rheum 1996; 39: 1747-1753. (Pubitemid 26331030)
15. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase -9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62:337-342.
16. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases- 2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32:368-372. (Pubitemid 28396484)
17. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141:211-217. (Pubitemid 32128725)
18. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585. (Pubitemid 36397324)
19. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006; 97:175-180 (Pubitemid 43139231)
20. Imai K, Yokohama Y, Nakanishi I, et al.. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. J Biol Chem 1995; 270: 66916697.
21. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996; 93: 97489753. (Pubitemid 26296680)
22. Jormsjo S, Whatling C, Walter DH, et al. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001; 21: 18341839. (Pubitemid 34219789)
23. Powell WC, Fingleton B, Wilson CL, et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Current Bio 1999; 9: 1441-1447. (Pubitemid 30023478)
24. Hasty KA, Jeffrey JJ, Hibbs MS, et al. The collagen substrate specificity of human neutrophil collagenases. J Biol Chem 1987; 262: 10048-10052. (Pubitemid 17103059)
25. Rekhter M, Zhang K, Narayanan A, et al. Type I collagen gene expression in human atherosclerosis: localization to specific plaque regions. Am J Pathol 1993; 143: 1634 1648. (Pubitemid 24058267)
26. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999; 99: 25032509. (Pubitemid 29228279)
27. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 1995; 92: 13931398.
28. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995; 91: 21252131.
29. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991; 88: 81548158. (Pubitemid 21915315)
30. Knauper V, Lopez-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996; 271: 15441550. (Pubitemid 26028643)
31. Horwitz AL, Hance AJ and Crystal RG. Granulocyte collagenase: selective digestion of type I relative to type III collagen. Proc Natl Acad Sci U S A. 1977; 74: 897901. (Pubitemid 8068710)
32. Welgus HG, Jeffrey JJ and Eisen AZ. The collagen substrate specificity of human skin fibroblast collagenase. J Biol Chem 1981; 256: 95119515. (Pubitemid 12234714)
33. Herman MP, Sukhova GK, Libby P, et.al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation, 2001 16; 104:1899-1904
34. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation. 2004; 110: 337343. (Pubitemid 38955503)
35. Wilson WR, Schwalbe EC, Jones JL, et al. Matrix metalloproteinase 8 (neutrophil collagenase) in the pathogenesis of abdominal aortic aneurysm. Br J Surg. 2005; 92: 828833. (Pubitemid 40961399)
36. Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP -8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2005; 187: 161169.
37. Zhou ZX, Qiang H, Ma AQ, et al. Measurement of peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006; 31: 258-262
38. Kato R, Momiyama Y, Ohmori R, et al. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J. 2005; 69:1035-1040 (Pubitemid 41603087)
39. Tuomainen AM, Nyyssönen K, Jari A, Laukkanen JA, et al. Serum Matrix Metalloproteinase-8 Concentrations are Associated with Cardiovascular Outcome in Men. Arterioscler Thromb, and Vasc Biol 2007; 27:2722. (Pubitemid 350158928)
40. Nilsson L, Jonasson L, Nijm J. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clin Chem. 2006; 1522-1527. (Pubitemid 44148315)
41. Furman C, Copin C, Kanoussi M, et al. Rosuvastain reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004; 174: 93-98. (Pubitemid 38595445)
42. Brew K, Dinakarpandian D and Nagas HU. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta 2000; 1477: 267-283. (Pubitemid 30119906)
43. Cavusoglu E, Ruwende C, Chopra V, et.al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101.e1-1101.e8.